Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB241 vs Rituximab in Untreated Diffuse Large B-cell Lymphoma
NCT03650933Phase 3Recruiting
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
- Start
- Dec 2018
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of GB241 in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Nanjing Yoko Biomedical Co., Ltd. Primary endpoint: Objective Response Rate at 18 weeks. Started Dec 2018; status: recruiting.
02
Drugs
GB241
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03650933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03650933.